Euroapi

Euroapi R&D Expenses

The Research & Development Expenses of Euroapi (EAPI.PA) as of Nov 2, 2026 is 27.30 M EUR. In the previous year, Research & Development Expenses was 25.80 M EUR — a change of 5.81% (higher).

R&D Expenses

27.30 MEUR

YoY

5.81%

Last updated:

Research & Development Expenses of Euroapi is 2025 27.30 M EUR. Research & Development Expenses of Euroapi was 2024 25.80 M EUR. It decreases by 5.81% higher compared to the previous year.

The Euroapi R&D Expenses history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D Expenses
Date
R&D Expenses
Jan 1, 2019
16.30 M EUR
Jan 1, 2020
19.90 M EUR
Jan 1, 2021
17.00 M EUR
Jan 1, 2022
21.80 M EUR
Jan 1, 2023
29.60 M EUR
Jan 1, 2024
25.80 M EUR
Jan 1, 2025
27.30 M EUR
The Euroapi R&D Expenses history
YEARR&D ExpensesYoY
27.30 MEUR+5.81%
25.80 MEUR-12.84%
29.60 MEUR+35.78%
21.80 MEUR+28.24%
17.00 MEUR-14.57%
19.90 MEUR+22.09%
16.30 MEUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Euroapi Stock analysis

What does Euroapi do? Euroapi SA generates revenue by manufacturing and supplying active pharmaceutical ingredient solutions to healthcare companies. The company develops and produces vitamin B12, prostaglandins, oligonucleotides, peptides, corticoids, hormones, anti-infectives, opiates including morphine, codeine, and thebaine, as well as analgesics. It offers Contract Development and Manufacturing Organization (CDMO) services through its Tides, Prostaglandins, Particle Engineering, Microbial Fermentation, Small Molecules Synthesis, Steroids and Hormones, and Opiates & Controlled Substances technologies. Healthcare partners purchase these products and services, with production sites across France, the United Kingdom, Germany, Italy, and Hungary supporting the supply chain. The company’s primary customers are healthcare companies seeking active pharmaceutical ingredient solutions. These clients buy products like vitamin B12, prostaglandins, and opiates, as well as CDMO services such as Microbial Fermentation and Steroids and Hormones development. Euroapi SA’s revenue streams are derived from both the direct sale of active ingredients and the provision of specialized manufacturing services through its CDMO division. Euroapi SA’s business model relies on its global production network in five countries to deliver tailored pharmaceutical solutions. The firm’s portfolio includes high-demand molecules such as opioids (morphine, codeine, thebaine) and hormone-based treatments, which are supplied to healthcare partners through its CDMO services. This dual approach of product sales and service-based manufacturing ensures steady revenue from established pharmaceutical markets. Euroapi is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Euroapi stock

Research & Development Expenses of Euroapi is 27.30 M EUR in 2025.

Research & Development Expenses of Euroapi changed from 25.80 M EUR to 27.30 M EUR, representing a 5.81% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Research & Development Expenses Euroapi since 2006 – with annual values, charts, and detailed analysis.

R&D expenses represent the costs incurred in researching and developing new products, services, or processes. High R&D spending can signal innovation and future growth potential.

Research & Development Expenses's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Research & Development Expenses's Euroapi historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Euroapi

All Key Metrics — Euroapi